BioCatalystWatch
TVRDWorkspace / TVRD / OverviewCompany library
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc. (TVRD)

Website

Price
Market cap
Next catalystEarly Q1 2027TTI-101 — REVERT LIVER CANCER · Phase 1/2 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

TTI-109

Small molecule

STAT3

Upcoming / outlook

  • Timing and evidence

TTI-101

STAT3

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

TTI-101

STAT3

PreINDP1P2P3FilingApproved
Upcoming / outlook

TTI-109

Small molecule

STAT3

Upcoming / outlook

  • Timing and evidence

Other pipelines

lead compound

STAT3

PreINDP1P2P3FilingApproved

Approved / commercial

History / paused

TTI-109

Small molecule

STAT3

PreINDP1P2P3FilingApproved
TTI-101

STAT3

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

TVRD PR & News

PR & News

TVRD SEC archive